Live Analyst Rating Changes 2092 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Travis Steed
BofA
Travis Steed
Wall Street Analyst
★★★☆☆
#1266
on 13Foresight · ranked by our own returns
39%
Success Rate
+2.3%
Average Return
22 of 56 calls profitable · -0.7% vs benchmark
📈 Across the calls we could measure, roughly 39% of Travis Steed's ratings turned a profit when each position was held for 1 year — averaging +2.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

155 Buy 68 Hold 16 Sell
Travis's Stock Coverage 41 ratings · 2026-06-23
Company Date Position Consensus Price Target 1-Yr Return
EW
Edwards Lifesciences
Jun 15, 2026 BUY Strong Buy
+13.1% avg upside
34 analysts
$100.00
16.49% Upside
+0.5%
GEHC
GE Healthcare Technologies Inc
Jun 12, 2026 HOLD Strong Buy
+37.4% avg upside
20 analysts
$74.00
22.02% Upside
-5.5%
ZBH
Zimmer Biomet Holdings
Jun 12, 2026 HOLD Buy
+28.1% avg upside
37 analysts
$100.00
14.66% Upside
+0.2%
SYK
Stryker
Jun 12, 2026 BUY Strong Buy
+24.8% avg upside
36 analysts
$380.00
24.76% Upside
-3.5%
MDT
Medtronic
Jun 12, 2026 BUY Buy
+23.6% avg upside
38 analysts
$95.00
19.95% Upside
-1.1%
ISRG
Intuitive Surgical
Jun 12, 2026 BUY Strong Buy
+30.6% avg upside
36 analysts
$515.00
27.72% Upside
-2.0%
BSX
Boston Scientific
Jun 12, 2026 BUY Strong Buy
+75.7% avg upside
38 analysts
$61.00
37.55% Upside
-3.5%
BDX
Becton Dickinson
Jun 12, 2026 HOLD Buy
+37.8% avg upside
25 analysts
$170.00
20.78% Upside
-1.6%
BAX
Baxter International
Jun 12, 2026 HOLD Buy
+51.0% avg upside
23 analysts
$24.00
22.09% Upside
-5.8%
ABT
Abbott Laboratories
Jun 12, 2026 BUY Strong Buy
+31.8% avg upside
35 analysts
$102.00
16.17% Upside
+0.3%
PODD
Insulet
Jun 10, 2026 BUY Strong Buy
+84.2% avg upside
32 analysts
$208.00
49.68% Upside
-3.3%
TNDM
Tandem Diabetes Care
Jun 08, 2026 HOLD Strong Buy
+125.1% avg upside
29 analysts
$25.00
74.34% Upside
-19.4%
MMED
MiniMed Group, Inc.
Jun 08, 2026 BUY Strong Buy
+50.9% avg upside
13 analysts
$20.00
40.74% Upside
·
DXCM
Dexcom
Jun 07, 2026 BUY Strong Buy
+42.8% avg upside
32 analysts
$80.00
15.85% Upside
-10.1%
HAE
Haemonetics
Jun 05, 2026 BUY Strong Buy
-7.7% avg upside
17 analysts
$80.00
10.24% Upside
·
MOBI
Mobia Medical, Inc.
Jun 02, 2026 BUY Strong Buy
+44.4% avg upside
4 analysts
$16.00
15.44% Upside
·
INSP
Inspire Medical Systems
May 22, 2026 SELL Buy
+101.0% avg upside
20 analysts
$39.00
5.78% Downside
+3.6%
BBNX
Beta Bionics, Inc.
May 21, 2026 HOLD Strong Buy
+53.5% avg upside
13 analysts
$13.00
5.04% Downside
+37.0%
EMBC
Embecta Corporation
May 18, 2026 SELL Sell
+146.8% avg upside
5 analysts
$3.00
0.97% Downside
·
CNMD
Conmed
May 18, 2026 HOLD Hold
+82.3% avg upside
12 analysts
$40.00
22.90% Upside
·
CBLL
Ceribell, Inc.
May 15, 2026 BUY Strong Buy
+37.9% avg upside
8 analysts
+12.8%
SOLV
Solventum Corporation
May 14, 2026 HOLD Buy
+16.1% avg upside
15 analysts
$85.00
15.66% Upside
+1.4%
RXST
RxSight
May 14, 2026 SELL Hold
+126.0% avg upside
13 analysts
-6.6%
IART
Integra Lifesciences
May 14, 2026 SELL Buy
+136.4% avg upside
21 analysts
-18.6%
SIBN
SI-Bone
May 13, 2026 BUY Strong Buy
+60.0% avg upside
18 analysts
+0.0%
MMSI
Merit Medical Systems
May 01, 2026 HOLD Strong Buy
+36.0% avg upside
15 analysts
$80.00
20.31% Upside
+0.9%
BLCO
Bausch + Lomb Corporation
Apr 30, 2026 SELL Buy
+30.4% avg upside
19 analysts
+4.5%
TFX
Teleflex
Apr 13, 2026 HOLD Buy
+46.3% avg upside
19 analysts
$135.00
10.93% Upside
-1.0%
KMTS
Kestra Medical Technologies Ltd.
Mar 18, 2026 BUY Strong Buy
+32.4% avg upside
7 analysts
-2.5%
COO
Cooper Co
Mar 05, 2026 BUY Strong Buy
+103.1% avg upside
21 analysts
$96.00
46.70% Upside
-18.4%
CARL
Carlsmed, Inc.
Feb 26, 2026 BUY Strong Buy
+86.2% avg upside
5 analysts
$17.00
72.84% Upside
-24.9%
GMED
Globus Medical
Feb 25, 2026 BUY Strong Buy
+21.0% avg upside
24 analysts
$106.00
33.89% Upside
-17.7%
PEN
Penumbra
Jan 15, 2026 BUY Buy
+4.7% avg upside
23 analysts
-9.8%
PRCT
PROCEPT BioRobotics
Nov 05, 2025 BUY Buy
+82.5% avg upside
16 analysts
-29.3%
ITGR
Integer Holdings
Oct 24, 2025 HOLD Strong Buy
+6.6% avg upside
15 analysts
$87.00
3.40% Downside
+23.6%
OM
Outset Medical
May 13, 2024 SELL Buy
+240.4% avg upside
8 analysts
$3.00
38.45% Downside
+62.9%
LUNG
Pulmonx
Sep 29, 2023 HOLD Strong Buy
+326.9% avg upside
9 analysts
-19.8%
DXC
DXC Technology
Jan 06, 2021 SELL Hold
+243.2% avg upside
22 analysts
$24.00
189.28% Upside
-27.5%
LNTH
Lantheus
Sep 27, 2017 BUY Strong Buy
-28.9% avg upside
20 analysts
$22.00
79.32% Downside
-17.1%
AXGN
AxoGen
Sep 25, 2017 BUY Strong Buy
-25.7% avg upside
21 analysts
$18.00
59.96% Downside
+98.4%
VRAYQ
Viewray
Aug 07, 2017 BUY Strong Buy
+558333233.3% avg upside
12 analysts
+89.5%
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Travis Steed — Frequently Asked Questions
How accurate are Travis Steed's stock ratings?
Based on the calls 13Foresight could measure, about 41% of Travis's ratings were profitable over a one-year hold, with an average return of +2.3% per rating, or -0.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Travis ranked on 13Foresight?
Travis Steed is currently ranked #1266 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Travis cover?
Travis most recently has ratings on EW, GEHC, ZBH, SYK, MDT, ISRG, BSX, BDX, BAX, ABT, PODD, TNDM and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.